GlassScriptPhysician profile
Jonathan Bouldin
NPI 1447735055
$9,592.42
in general payments reported to CMS, 2019-2025
32 companies · $41.34 in 2025
The $41.34 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,956 · 2022: $2,975 · 2023: $4,304 · 2024: $316 · 2025: $41.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645 · Education: $16.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,645.18 |
| Education | $16.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,602.70 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,380.82 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $1,087.53 | 2021-2023 | Entyvio, Gattex, Vpriv |
| Janssen Biotech, INC. | $539.37 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $331.62 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $289.05 | 2021-2023 | Rebyota, Clenpiq |
| Celgene Corporation | $282.22 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $233.77 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $223.27 | 2022-2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $195.53 | 2021-2023 | |
| Braintree Laboratories, INC. | $189.80 | 2021-2023 | Sutab |
| Daiichi Sankyo INC. | $179.82 | 2021-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $173.00 | 2023-2024 | Ocaliva |
| Genzyme Corporation | $141.81 | 2022-2023 | |
| Ardelyx, INC. | $111.90 | 2022-2024 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $82.98 | 2022-2025 | Interstim |
| Pfizer INC. | $50.27 | 2022-2024 | |
| Amgen INC. | $48.83 | 2022-2023 | Amjevita, Avsola |
| Organon LLC | $48.28 | 2022-2023 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.80 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $43.57 | 2022 | |
| Qol Medical, LLC | $40.49 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $39.50 | 2023 | Linzess |
| Mylan Institutional INC. | $36.81 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $34.80 | 2023 | Zeposia |
| Lilly USA, LLC | $31.59 | 2023 | Mounjaro |
| Redhill Biopharma INC. | $29.93 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $27.11 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.55 | 2021 | |
| Celltrion USA INC. | $16.32 | 2023 | Zymfentra, Yuflyma |
| Recordati_rare_diseases_inc. | $15.62 | 2023 | Panhematin |
| Mallinckrodt Hospital Products INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bouldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.